Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Netflix’s $72 Billion Warner Bros Discovery Deal Reshapes the Entertainment Landscape 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Waymo Issues Recall After Reports of Self-Driving Cars Illegally Passing School Buses in Texas 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Boeing Acquisition of Spirit AeroSystems Could Close Soon Amid Ongoing Conditions 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Novo Nordisk (NYSE:NVO) forecasted slower sales growth for 2025, reflecting an expected moderation in demand for its blockbuster obesity drug, Wegovy. The Danish pharmaceutical giant projects local currency sales growth between 16% and 24%, down from 26% in 2024 but aligning with analysts' expectations of around 20%.
Novo Nordisk faces increasing competition from Eli Lilly (NYSE:LLY), a key rival in the weight-loss drug market. Despite this, the company reported strong fourth-quarter results, with operating profit surging 37% to 36.7 billion Danish crowns ($5.12 billion), surpassing analysts' estimates of 33.6 billion. For 2025, the company expects operating profit growth between 19% and 27%, compared to last year's 26%.
Wegovy sales more than doubled in Q4, reaching 19.9 billion crowns, up from 9.6 billion a year earlier and exceeding the 17.3 billion recorded in Q3. The sustained demand underscores the drug’s strong market position, although future growth is expected to decelerate.
As the weight-loss drug market evolves, Novo Nordisk continues to navigate supply constraints and rising competition. Investors remain focused on the company’s long-term outlook as it balances expansion efforts with growing market challenges.
